Sophia Genetics (SOPH) and Complete Genomics said Tuesday they are collaborating to expand access to precision oncology testing.
Sophia Genetics will integrate its MSK-IMPACT and MSK-ACCESS applications with sequencing technology from Complete Genomics to deliver an integrated, sample-to-report workflow for cancer genomic profiling, the companies said.
Shares of Sophia Genetics were up over 3% in recent trading.
Price: 4.45, Change: +0.10, Percent Change: +2.18